Tarsus Pharmaceuticals

Tarsus is a late clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives, starting with Demodex blepharitis. Tarsus is developing a pipeline of products, with the lead candidate, TP-03, in clinical development to treat Demodex blepharitis. TP-03 is a novel, topical ophthalmic drug that specifically targets the Demodex mite’s nervous system, thereby treating the underlying cause of disease.